Inhibrx Granted Fast Track Designation For INBRX-101 For Treatment Of Alpha-1 Antitrypsin Deficiency
Portfolio Pulse from Benzinga Newsdesk
Inhibrx, Inc. (NASDAQ:INBX) has been granted Fast Track designation by the FDA for INBRX-101, a treatment for patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).
May 30, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inhibrx's INBRX-101 receives FDA Fast Track designation, potentially accelerating the development and approval process for the treatment of emphysema due to AATD.
The FDA Fast Track designation for INBRX-101 is a positive development for Inhibrx, as it may accelerate the development and approval process for the treatment. This could lead to faster market entry and revenue generation, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100